KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Work In Process (2018 - 2026)

Twist Bioscience has reported Work In Process over the past 9 years, most recently at $2.9 million for Q1 2026.

  • Quarterly Work In Process rose 90.36% to $2.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Mar 2026, up 90.36% year-over-year, with the annual reading at $2.3 million for FY2025, 5.55% up from the prior year.
  • Work In Process was $2.9 million for Q1 2026 at Twist Bioscience, up from $2.3 million in the prior quarter.
  • Over five years, Work In Process peaked at $3.9 million in Q2 2022 and troughed at $611000.0 in Q2 2023.
  • The 5-year median for Work In Process is $2.3 million (2025), against an average of $2.3 million.
  • Year-over-year, Work In Process plummeted 84.25% in 2023 and then surged 262.19% in 2024.
  • A 5-year view of Work In Process shows it stood at $3.6 million in 2022, then plummeted by 33.8% to $2.4 million in 2023, then rose by 10.33% to $2.6 million in 2024, then decreased by 12.02% to $2.3 million in 2025, then rose by 26.85% to $2.9 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Work In Process are $2.9 million (Q1 2026), $2.3 million (Q4 2025), and $2.3 million (Q3 2025).